For the quarter ending 2026-03-31, CYCN has $8,505K in assets. $2,823K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 2,823 | 3,240 | 4,568 | 3,006 |
| Accounts receivable | 0 | 1,000 | 100 | 525 |
| Prepaid expenses | 255 | 384 | 386 | 462 |
| Other current assets | 11 | 11 | 11 | 27 |
| Total current assets | 3,089 | 4,635 | 5,065 | 4,020 |
| Property, plant and equipment, net | 66 | - | - | - |
| Other investment | 5,350 | 5,350 | 5,350 | 5,350 |
| Total assets | 8,505 | 9,985 | 10,415 | 9,370 |
| Accounts payable | 457 | 508 | 480 | 462 |
| Accrued research and development costs | 148 | 198 | 46 | 72 |
| Accrued expenses and other current liabilities | 1,109 | 194 | 351 | 266 |
| Total current liabilities | 1,714 | 900 | 877 | 800 |
| Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of series a convertible preferred stock issued and outstanding at march 31, 2026 and december 31, 2025 | 0 | 0 | 0 | 0 |
| Common stock, no par value, 400,000,000 shares authorized at march 31, 2026 and december 31, 2025 2025 4,330,314 and 3,925,314 shares issued at march 31, 2026 and december 31, 2025, respectively 4,241,260 and 3,821,236 shares outstanding at march 31, 2026 and december 31, 2025, respectively | 0 | 0 | 0 | 0 |
| Paid-in capital | 280,988 | 280,105 | 279,759 | 277,815 |
| Accumulated deficit | -274,197 | -271,020 | -270,221 | -269,245 |
| Total stockholders' equity | 6,791 | 9,085 | 9,538 | 8,570 |
| Total liabilities and stockholders' equity | 8,505 | 9,985 | 10,415 | 9,370 |
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)